New drug aims to boost walking ability in adults with muscle-weakening disease
NCT ID NCT05794139
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 34 times
Summary
This study tests an experimental drug called NMD670 in 54 adults with type 3 spinal muscular atrophy, a condition that causes muscle weakness. Participants take the drug or a placebo for a period, then switch, to see if the drug improves walking distance and muscle strength. The goal is to find a safe treatment that eases symptoms and improves daily function.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SPINAL MUSCULAR ATROPHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AOU Città della Salute e della Scienza di Torino
Torino, Italy
-
Aarhus Universitetshospital, Neurologisk Afdeling
Aarhus, Denmark
-
CHR de la Citadelle - Neurologie
Liège, Belgium
-
Charite - Campus Virchow-Klinikum (CVK)
Berlin, Germany
-
Genge Partners Inc.
Montreal, Canada
-
Heritage Medical Research Clinic
Calgary, Canada
-
Hospital Materno Infantil La Paz
Madrid, Spain
-
Hospital Universitari Vall D Hebron
Barcelona, Spain
-
Hospital Universitario y Politécnico La Fe
Valencia, Spain
-
Istituto Giannina Gaslini, IRCCS
Genova, Italy
-
Istituto Neurologico C. Besta, Fondazione IRCCS
Milan, Italy
-
Neurology Rare Disease Center
Denton, Texas, 76208, United States
-
Ospedale Niguarda, ASST Grande Ospedale Metropolitano Niguarda
Milan, Italy
-
Rare Disease Research - Raleigh-Durham
Hillsborough, North Carolina, 27278, United States
-
Rigshospitalet - Neurologisk Afdeling
Copenhagen, Denmark
-
Roy Blunt NextGen Precision Health Institute
Columbia, Missouri, 65212, United States
-
Stanford University Medical Center
Palo Alto, California, 94304, United States
-
The Johns Hopkins Medicine, Spinal Muscular Atrophy Center
Baltimore, Maryland, 21287, United States
-
The Ohio State University Wexner Medical Center
Columbus, Ohio, 43210, United States
-
UCLA David Geffen School Of Medicine - Neurology
Los Angeles, California, 90095, United States
-
UZ Leuven - Neurochirurgie Campus Gasthuisberg
Leuven, Belgium
-
Universitair Medisch Centrum Utrecht, locatie Academisch Zie - Neurology
Utrecht, Netherlands
-
University of Kansas Medical Center
Kansas City, Kansas, 66160, United States
-
Universitätsklinikum Essen - Klinik Für Neurologie
Essen, Germany
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.